Plaque-based enhancement assay The protocol for ADE assay has been previously described [36]. Briefly, pre-formed antibody-DNEV complex were prepared by incubating serially 10-fold diluted antibody with Luc-DENV at MOI of 0.5 in 37°C before applying to 1 × 105 K562 cells in 12-well plates. Cells were incubated for additional 72 hours,

and the CAL-101 manufacturer virus titer in the supernatant was titrated by standard plaque assay on BHK-21 cells. Luc-based enhancement assay The Luc-based ADE assay was operated similar with plaque-based enhancement assay as above described in 12-well plates. Serial dilutions of antibodies mixed with Luc-DENV were incubated for 72 hours on K562 cells, cell lysates were then subjected to luciferase activities assay as described above. The enhancing activity was evaluated by comparing the RLU value from cells harboring antibody-Luc-DENV complex and that from cells harboring Luc-DENV alone. Statistical analysis All statistical analyses were performed using SPSS 13.0. Graphs were performed using the Prism software (GraphPadPrism5, San Diego, CA). The data were presented as means plus standard deviations from there independent experiments.

A P value < 0.05 was considered statistically significant. Acknowledgements This study was supported in part by the National Basic Research Project of China (No.2012CB518904) and National Natural Science Foundation of China (No.31000083, No.81101243 and No.31270974). Electronic supplementary material Additional file 1: Figure

S1: Growth curve of Luc-DENV on ACP-196 ic50 BHK-21 cells expressed by luciferase activity. Cells were infected with virus at MOI of 0.5, collected and lysed at the indicated time points to measure the luciferase activities. Each data point represents the mean obtained in three separate assays with SD (indicated by bars). (TIFF 56 KB) Additional file 2: Figure S2: Growth Palbociclib concentration curve of Luc-DENV on K562 cells expressed by luciferase activity. Cells were infected with virus at MOI of 0.5, collected and lysed at the indicated time points to measure the luciferase activities. Each data point represents the mean obtained in three separate assays with SDs (indicated by bars). (TIFF 51 KB) References 1. Gubler DJ: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002, 10:100–103.PubMedCrossRef 2. Simmons CP, Farrar JJ, Nguyen vV, Wills B: Dengue. N Engl J Med 2012, 366:1423–1432.PubMedCrossRef 3. Adams B, Holmes EC, Zhang C, Mammen MP Jr, Nimmannitya S, Kalayanarooj S, Boots M: Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A 2006, 103:14234–14239.PubMedCentralPubMedCrossRef 4. Halstead SB: Dengue. Lancet 2007, 370:1644–1652.PubMedCrossRef 5. Halstead SB: Neutralization and antibody-dependent enhancement of dengue viruses.